Immutep Limited (IMMP)
NASDAQ: IMMP · Real-Time Price · USD
1.720
-0.020 (-1.15%)
At close: Aug 1, 2025, 4:00 PM
1.750
+0.030 (1.74%)
After-hours: Aug 1, 2025, 5:08 PM EDT
United States Steel Revenue
Immutep had revenue of 3.15M AUD in the half year ending December 31, 2024, with 86.75% growth. This brings the company's revenue in the last twelve months to 4.88M, up 24.11% year-over-year. In the fiscal year ending June 30, 2024, Immutep had annual revenue of 3.84M with 9.59% growth.
Revenue (ttm)
4.88M AUD
Revenue Growth
+24.11%
P/S Ratio
81.57
Revenue / Employee
157,381 AUD
Employees
31
Market Cap
246.29M USD
Revenue Chart
* This company reports financials in AUD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2024 | 3.84M | 336.16K | 9.59% |
Jun 30, 2023 | 3.51M | -1.21M | -25.64% |
Jun 30, 2022 | 4.71M | 851.56K | 22.04% |
Jun 30, 2021 | 3.86M | -9.88M | -71.88% |
Jun 30, 2020 | 13.74M | 8.10M | 143.72% |
Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
IMMP News
- 2 days ago - Immutep Quarterly Activities Report Q4 FY25 - GlobeNewsWire
- 3 days ago - Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer - GlobeNewsWire
- 2 months ago - Immutep's Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma - GlobeNewsWire
- 2 months ago - Immutep Reports 61% Response Rate In Lung Cancer Trial With Keytruda-Based Triple Combo - Benzinga
- 3 months ago - Immutep Limited: Surging On Positive Head And Neck Data - Seeking Alpha
- 4 months ago - Immutep to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 6 months ago - Immutep Quarterly Activities Report Q2 FY25 - GlobeNewsWire
- 6 months ago - Immutep Limited: Continuing To Make The Case For Eftilagimod - Seeking Alpha